Probiotec Ltd
ASX:PBP
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.1259
2.9924
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PBP stock under the Base Case scenario is 3.96 AUD. Compared to the current market price of 2.98 AUD, Probiotec Ltd is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Probiotec Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PBP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Probiotec Ltd
Balance Sheet Decomposition
Probiotec Ltd
Current Assets | 72.6m |
Cash & Short-Term Investments | 12.8m |
Receivables | 34.7m |
Other Current Assets | 25.1m |
Non-Current Assets | 158.8m |
PP&E | 61.2m |
Intangibles | 84.1m |
Other Non-Current Assets | 13.5m |
Current Liabilities | 46m |
Accounts Payable | 30.7m |
Other Current Liabilities | 15.3m |
Non-Current Liabilities | 97.1m |
Long-Term Debt | 79.1m |
Other Non-Current Liabilities | 18m |
Earnings Waterfall
Probiotec Ltd
Revenue
|
221.2m
AUD
|
Cost of Revenue
|
-155m
AUD
|
Gross Profit
|
66.3m
AUD
|
Operating Expenses
|
-46.2m
AUD
|
Operating Income
|
20m
AUD
|
Other Expenses
|
-11.3m
AUD
|
Net Income
|
8.7m
AUD
|
Free Cash Flow Analysis
Probiotec Ltd
AUD | |
Free Cash Flow | AUD |
PBP Profitability Score
Profitability Due Diligence
Probiotec Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Probiotec Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
PBP Solvency Score
Solvency Due Diligence
Probiotec Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Probiotec Ltd's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBP Price Targets Summary
Probiotec Ltd
Dividends
Current shareholder yield for PBP is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
PBP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-11-14. The firm owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. The Company’s products are manufactured on behalf of a range of clients, including international companies. The company also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics and food, and beverage companies. The firm subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd and Willie Labs Generics Pty Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one PBP stock under the Base Case scenario is 3.96 AUD.
Compared to the current market price of 2.98 AUD, Probiotec Ltd is Undervalued by 25%.